Introduction
============

Cellular phone technology is a promising tool for antiretroviral therapy (ART) adherence support \[[@R1]\], although findings have been mixed. Adherence improved with weekly short message service (SMS) reminders in Kenya \[[@R2],[@R3]\] and twice weekly SMS reminders in Nigeria \[[@R4]\], whereas no benefit was observed with weekly SMS reminders in Cameroon \[[@R5]\] and India \[[@R6]\], or with SMS reminders 5 days a week in Brazil \[[@R7]\].

Real-time adherence monitoring can be accomplished through pill bottles that record a date-and-time stamp for each opening, which is then transmitted over cellular networks. It is the only monitoring approach that can trigger an intervention precisely when needed. Two recent studies assessed the combination of real-time adherence monitoring with SMS reminders triggered by late or missed doses. One in China showed an improvement in overall adherence \[[@R8]\], whereas one in South Africa did not \[[@R9]\], although the latter found fewer sustained adherence lapses. SMS could also be used to engage social support systems, which have been shown to be important for ART adherence \[[@R10]--[@R12]\]; however, this type of intervention has not been previously studied.

Given the variable results in the literature, we conducted a pilot randomized controlled trial of multiple types of interventions based on SMS and real-time adherence monitoring to improve adherence among individuals initiating ART in Uganda.

Methods
=======

Setting
-------

Participants were recruited from the Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda, which cares for ∼10 000 HIV-positive individuals. The region is largely rural and approximately one-quarter of homes have electricity.

Participants
------------

This study involved two types of participants: individuals taking ART ('study participants') and their 'social supporters'. Inclusion criteria for study participants were: being 18+ years, initiating ART, owning a personal cell phone with reliable reception, willing and able to identify one to two social supporters, and living less than 20 km from MRRH (to facilitate participant follow-up). Inclusion criteria for social supporters were: being 18+ years, owning a personal cell phone with a reliable reception, knowing the study participant\'s HIV status, living less than 20 km from MRRH, and reporting prior provision of social support to the study participant (i.e. instrumental support to attend clinic or motivational support to take medicine). Exclusion criteria for both participant types were: inability to use SMS, unwillingness to have cellular reception confirmed at home, and inability to provide informed consent.

Procedures
----------

All study participants received a real-time adherence monitor (Wisepill Technologies, Cape Town, South Africa) and were followed for 9 months. Monitor openings during periods of inadequate cellular reception were stored for later transmission. Participants were given solar chargers and sent an SMS to charge the monitor as needed.

A simple random number generator was used to determine study arm assignments. The study coordinator informed research assistants of the arm assignment at enrolment. Participants were randomized 1 : 1 : 1 as follows:Scheduled SMS + real-time adherence monitoring ('scheduled SMS arm') -- Study participants received an SMS reminder daily for 1 month, then weekly for 2 months. For the next 6 months, study participants received an SMS only if no signal was received from the monitor within 2 h of the expected dosing time, and an SMS notification was sent to one to two social supporters if no signal was received for more than 48 h.Triggered SMS + real-time adherence monitoring ('triggered SMS arm') -- For the whole 9 months, study participants received an SMS only if no signal was received from the monitor within 2 h of the expected dosing time. For the latter 6 of the 9 months, an SMS notification was sent to one to two social supporters if no signal was received for \>48 h.Real-time adherence monitoring only (called the 'control') -- Study participants in this arm received no SMS reminders.

Social supporters were encouraged to support the study participant\'s adherence, but were not given specific guidance. All SMS content could be personalized; the default message was 'This is your reminder'. Scheduled SMS were sent at participant-specified times.

Participants completed a questionnaire regarding sociodemographics, health, depression \[[@R13]\], food insecurity \[[@R14]\], alcohol use \[[@R15]\], social support \[[@R16]\], and HIV stigma \[[@R17]\]. HIV RNA was determined at months 3 and 9 (Cobas Taqman Test, Roche, Switzerland). Social supporters were enrolled during month 3 to ensure ongoing relationships when the SMS notifications began. Qualitative interviews conducted during the study are presented in a companion article \[[@R18]\].

Analysis
--------

Assuming a standard deviation of 10%, we determined a sample size of 63 would allow 84% power to detect an increase in mean adherence from 80 to 90% for each arm compared with control. Study participant characteristics were compared across study arms with Fisher\'s exact test and the Wilcoxon rank-sum test. Our primary outcome of interest was adherence (calculated as the number of monitor opening signals received divided by the number of monitor opening signals expected, and capped at 100%). Monitor openings by staff were removed. A secondary dataset was created in which suspected technical difficulties or monitor nonuse per participant report was censored. Although subject to recall and social desirability biases, the secondary dataset may decrease misclassification bias. In an intention-to-treat analysis, percentage doses taken each month were compared by linear generalized estimating equations (GEEs); more than 48-h and more than 96-h lapses in dosing were compared by Poisson GEE regression. HIV RNA suppression (\<100 copies/ml) was compared among study arms by Fisher\'s exact test. To compare adherence with HIV RNA, we ran the rank-sum test for median adherence among participants with suppressed versus unsuppressed HIV RNA. Loss to follow-up was defined as no contact or adherence data for 3 months. Missing adherence data was considered as nonadherence; HIV RNA was considered unsuppressed if no blood sample was obtained. All analyses were conducted in Stata (StataCorp., College Station, Texas, USA).

Ethics
------

Human subject approval was obtained from Mbarara University of Science and Technology, Uganda National Council of Science and Technology, and Partners Healthcare.

Results
=======

Participant characteristics
---------------------------

Between September 2013 and October 2014, 195 individuals were screened to identify 63 eligible study participants. Reasons for exclusion were (multiple criteria applied to some individuals):Lived more than 20 km from MRRH: 75 (57%)No personal cell phone: 49 (37%)Not willing or able to name one to two social supporters: 20 (15%)Unwilling to have cell reception tested at home: 6 (5%)Inability to provide informed consent: 3 (2%)Inadequate cellular reception: 2 (2%)Less than 18 years old: 1 (1%)

Twenty-one participants were assigned to the scheduled SMS arm, 20 to the triggered SMS arm, and 21 to the control. One participant was found to be HIV-negative after randomization and disenrolled; data for this participant were excluded from analysis. Forty-eight individuals were identified as social supporters, of whom 45 enrolled; the three ineligible individuals lived more than 20 km from MRRH. Follow-up concluded as planned in June 2015.

Fifty-eight (94%) study participants completed the study with a median follow-up of 8.9 months \[interquartile range (IQR) 8.7--8.9\]. Four study participants were lost to follow-up (two in the triggered SMS arm, two in the control). Forty-one social supporters completed the study. One social supporter died, one was lost-to-follow-up, and two were disenrolled per the study participant\'s request.

Participant characteristics are presented in Table [1](#T1){ref-type="table"}. All were similar among study arms with the exception of female gender (71% in the schedule SMS arm, 35% in the triggered SMS arm, 86% in the control; *P* = 0.03).

SMS
---

During the study, 3436 (63%) SMS were sent as planned and 1935 (36%) were sent unnecessarily (i.e. the monitor was opened, but no signal was received until after an SMS had been sent). Forty-four (1%) SMS were not sent because of technical challenges (e.g. network outages).

Adherence
---------

Percentage adherence was 11.1% higher (*P* = 0.02) and more than 48-h and more than 96-h lapses were less frequent \[incremental risk ratio (IRR) 0.6, *P* = 0.02 and IRR 0.3, *P* \< 0.001, respectively\] in the scheduled SMS arm compared with the control (Table [2](#T2){ref-type="table"}). Adherence was similar in the triggered SMS arm and control, although the frequency of more than 96-h adherence lapses showed a downward trend in the triggered SMS arm.

In the secondary dataset, 2% of participant-days were censored for suspected monitor nonuse and 3% for technical difficulties; no statistically significant differences in the analysis were seen. No statistically significant differences were seen when controlling for sex differences among study arms.

HIV RNA suppression
-------------------

HIV RNA was suppressed in 53 of 62 (85%) participants at months 3 and 9, although only 47 participants were suppressed at both time points. No statistically significant differences in HIV RNA suppression were seen among study arms (*P* = 0.14); however, adherence correlated with HIV RNA. At month 9, median adherence was 91 (IQR 82--96) for participants with suppressed HIV RNA versus 57 (IQR 47--78) for those with unsuppressed HIV RNA (*P* \< 0.001).

Discussion
==========

In the context of real-time monitoring, daily and then weekly scheduled SMS reminders starting at ART initiation improved adherence compared with real-time monitoring alone, whereas SMS reminders linked to late or missed doses did not. Our findings confirm the positive impact of fixed interval reminders in prior studies \[[@R2]--[@R4]\]. In one of these studies, daily reminders were not effective, but weekly reminders were \[[@R3]\]; however, daily messages were sent for 48 consecutive weeks, potentially causing habituation. The decreasing frequency of SMS reminders in this study may have avoided that phenomenon.

Although prior studies saw significant benefit in overall adherence \[[@R8]\] and adherence lapses \[[@R9]\] with SMS linked to real-time detection of late or missed doses, we did not. Potential explanations include the overall high adherence in this study and the small sample size. Additionally, qualitative data from this study (presented separately) \[[@R18]\] indicate that scheduled reminders were experienced as supportive, whereas triggered reminders could be received too late to be effective (i.e., after participants were asleep).

The lack of definitive benefit from SMS notifications to social supporters was surprising. Social support has been shown previously to be important for ART adherence (e.g., via access to resources and reduced stigma) \[[@R10]--[@R12]\]. Detailed assessment of the support provided and relationship dynamics between study participants and social supporters will be important to understand this finding.

Similar viral suppression among study arms is consistent with the two other studies of real-time adherence interventions \[[@R8],[@R9]\]. Importantly, this study was not powered for differences in viral suppression. It is possible that differences in virologic outcomes could be seen in a larger study with longer follow-up.

This study has important limitations. Real-time monitoring in the control group likely has its own intervention effect and may have limited the ability to detect intervention effects from SMS in the other study arms -- a phenomenon explored in the separately presented qualitative findings \[[@R18]\]. Additionally, 37% of screened participants were excluded because they lacked access to a personal cell phone. Participants may have had relatively high socioeconomic status, thus limiting generalizability.

In summary, we found that scheduled SMS significantly increased adherence in individuals initiating ART in Uganda. The technology employed for real-time adherence monitoring and accompanying SMS was successfully implemented despite limited resources. Future work should assess costs of this technology to inform scalability. Studies are also needed to determine the benefits associated with SMS alone versus SMS tied to real-time adherence monitoring.
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###### 

Study participant and social supporter characteristics at enrolment.

                                                           Study participants (*N* = 62)                Social supporters (*N* = 45)
  -------------------------------------------------------- -------------------------------------------- ------------------------------
  Female                                                   40 (65%)[^a^](#TF1-1){ref-type="table-fn"}   31 (69%)
  Median age (years)                                       30 (25--35)                                  35 (31--46)
  Education                                                                                             
   None                                                    5 (8%)                                       3 (7%)
   Primary                                                 36 (58%)                                     22 (49%)
   Greater than primary                                    21 (34%)                                     20 (44%)
  Able to read English or Runyankole                       60 (97%)                                     43 (96%)
  Median CD4^+^ cell count (cells/μl)                      309 (231--397)                               n/a
  ART regimen                                                                                           
   TDF-3TC-EFV                                             60 (97%)                                     n/a
   ZDV-3TC-NVP                                             2 (3%)                                       n/a
  Severe food insecurity                                   23 (37%)                                     14 (31%)
  Depression                                               30 (48%)                                     1 (2%)
  Hazardous alcohol use                                    14 (23%)                                     6 (13%)
  Social support score[^b^](#TF1-2){ref-type="table-fn"}   3.1 (2.8--3.4)                               3.1 (2.6--3.7)
  Stigma score[^c^](#TF1-3){ref-type="table-fn"}           3 (2--5)                                     0 (0--1.25)

Social supporters were only enrolled for study participants in the intervention arms. ART, antiretroviral therapy; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine; 3TC, lamivudine.

^a^Female gender was noted to be different among the randomized study arms (71% in the schedule SMS arm, 35% in the triggered SMS arm, 86% in the control; *P* = 0.03). All other characteristics were similar among study arms.

^b^This score ranges from 1 to 4, with 4 indicating high levels of social support.

^c^This score ranges from 1 to 8, with 8 indicating high levels of stigma.

###### 

Comparison of adherence by study arm over the 9-month study period.

                                      Study arm                          
  ----------------------------------- ------------------- -------------- --------------
  Percentage adherence                                                   
   Median (IQR)                       92% (88--99)        84% (66--93)   90% (72--93)
   Mean (SD)                          91% (9)             79% (18)       79% (22)
   Intervention effect (*P* value)    **11.1 (0.02)**     −0.7 (0.90)    ref
  Lapses in adherence                                                    
   More than 48 h                                                        
    Median (IQR)                      5 (1--11)           8 (4--16)      6 (3--19)
    Mean (SD)                         7 (8)               11 (10)        11 (11)
    Intervention effect (*P* value)   **0.6 (0.02)**      1.0 (0.80)     ref
   More than 96 h                                                        
    Median (IQR)                      1 (0--1)            2 (0--6)       2 (1--3)
    Mean (SD)                         1 (2)               3 (3)          4 (5)
    Intervention effect (*P* value)   **0.3 (\<0.001)**   0.7 (0.23)     ref

Intervention effects for percentage adherence reflect the difference in mean adherence, whereas intervention effects for lapses in the real-time monitoring signal indicate the incremental risk ratio. These results were found in the primary dataset in which only staff openings were censored. Results for the secondary dataset, in which suspected technical difficulties and device nonuse were also censored, were similar. IQR, interquartile range; SD, standard deviation. Significant values (*P* \< 0.05) are bolded.
